<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150657</url>
  </required_header>
  <id_info>
    <org_study_id>AVF3121s</org_study_id>
    <nct_id>NCT00150657</nct_id>
  </id_info>
  <brief_title>Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer</brief_title>
  <official_title>Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. John Providence Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. John Providence Health System</source>
  <brief_summary>
    <textblock>
      -  this study is being done to find out if the combination of carboplatin and gemcitabine
           will be more effective in the the treatment of advanced lung cancer if bevacizumab, an
           agent that blocks tumor blood vessel formation, is added

        -  the study will measure the time to progression of patients treated with the combination;
           we hope to show that the addition of bevacizumab improves the time to progression
           (increases the amount of time before the disease begins to worsen)

        -  all patients receive all three drugs; there is no placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung
           cancer with non-squamous histology, good performance status, and adequate organ function
           are eligible.

        -  Patients with brain metastases, squamous histology, or hemoptysis are excluded.

        -  All patients must give informed consent.

        -  Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg
           IV day 1 repeated every 21 days for 6 cycles
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>two year survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or
             recurrent after previous surgery and/or radiation therapy

          -  Stage IV disease or stage IIIB with a malignant pleural effusion

          -  measurable or evaluable disease

          -  Performance status 0 or 1 (ECOG)

          -  adequate renal, hepatic, and bone marrow function

          -  adequate recovery from previous surgery or radiotherapy

          -  informed consent

        Exclusion Criteria:

          -  brain metastases

          -  squamous (epidermoid) histology

          -  hemoptysis

          -  central airway disease

          -  Pancoast tumors

          -  previous chemotherapy or biologic therapy for lung cancer

          -  prior malignancy within the previous 5 years except non-melanoma skin cancer or
             cervical CIS

          -  pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Kraut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Kraut, MD</last_name>
    <phone>248-849-3541</phone>
    <email>mkraut@providence-hospital.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaswinder Grewal, PhD</last_name>
    <phone>248-849-5337</phone>
    <email>jgrewal@providence-hospital.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Kraut, MD</last_name>
      <phone>248-849-8155</phone>
      <email>mkraut@providence-hospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Howard Terebelo, DO</last_name>
      <phone>248-552-0620</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael J Kraut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Terebelo, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anibal Drelichman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Bloom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lyle Goldman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judie Goodman, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>November 28, 2005</last_update_submitted>
  <last_update_submitted_qc>November 28, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

